Category: 41575-94-4

The preparation of ester heterocycles mostly uses heteroatoms as nucleophilic sites, which are achieved by intramolecular substitution or addition reactions. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)( cas:41575-94-4 ) is researched.Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II).Aghajanian, Carol; Swisher, Elizabeth M; Okamoto, Aikou; Steffensen, Karina Dahl; Bookman, Michael A; Fleming, Gini F; Friedlander, Michael; Moore, Kathleen N; Tewari, Krishnansu S; O’Malley, David M; Chan, John K; Ratajczak, Christine; Hashiba, Hideyuki; Wu, Meijing; Dinh, Minh H; Coleman, Robert L published the article 《Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial.》 about this compound( cas:41575-94-4 ) in Gynecologic oncology. Keywords: Dose-dense paclitaxel; Homologous recombination deficiency; Ovarian cancer; PARP inhibitor; Veliparib; gBRCA. Let’s learn more about this compound (cas:41575-94-4).

OBJECTIVE: In the Phase 3 VELIA trial (NCT02470585), veliparib added to carboplatin plus paclitaxel concomitantly and as maintenance for women with newly-diagnosed advanced ovarian cancer significantly improved progression-free survival (PFS) versus chemotherapy alone. Here we present exploratory analyses by paclitaxel dosing schedule and germline BRCA (gBRCA) status. METHODS: Women with untreated ovarian carcinoma were randomized (1:1:1) to: veliparib during chemotherapy and maintenance (veliparib-throughout), veliparib during chemotherapy followed by placebo maintenance (veliparib-combination only), or placebo during chemotherapy and maintenance (control). Chemotherapy included carboplatin plus dose-dense (DD; weekly) or every-3-week (Q3W) paclitaxel (a stratification factor at randomization), selected at the investigator’s discretion pre-randomization. PFS was assessed by paclitaxel dosing schedule using a Cox proportional hazard model adjusted by treatment arm and stratification factors; safety was analyzed based on paclitaxel dosing schedule and gBRCA status. RESULTS: 1132 patients were analyzed by paclitaxel schedule. Pooled treatment arms demonstrated longer median PFS with DD (n = 586) versus Q3W (n = 546) paclitaxel (ITT: 20.5 vs 15.7 months, hazard ratio [HR] 0.77; homologous recombination proficient cancer: 15.1 vs 11.8 months, HR 0.64; BRCAwt: 18.0 vs 12.9 months, HR 0.70). Comparison between arms favored veliparib-throughout versus control in both DD (PFS, 24.2 vs 18.3 months, hazard ratio 0.67) and Q3W (19.3 vs 14.6, hazard ratio 0.69) subgroups. DD paclitaxel was associated with higher incidence of Grade 3/4 neutropenia, fatigue, and anemia versus Q3W. There were no differences in toxicity between gBRCAm (n = 211) and gBRCAwt (n = 902) subgroups. CONCLUSIONS: DD paclitaxel was tolerable and associated with longer PFS in the HR proficient and gBRCAwt groups, versus Q3W. gBRCA status did not impact safety.

Compounds in my other articles are similar to this one(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), you can compare them to see their pros and cons in some ways,such as convenient, effective and so on.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Name: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Investigation of Hypersensitivity Reactions in Carboplatin Desensitization Therapy..

BACKGROUND/AIM: Carboplatin is a key drug in the treatment of ovarian cancer, but hypersensitivity reactions (HSRs) may occur with repeated use. PATIENTS AND METHODS: Thirty-seven ovarian cancer patients treated with carboplatin desensitization therapy were reviewed retrospectively. The treatment completion rate and toxicity were examined. RESULTS: The carboplatin desensitization completion rate was 86.5%. Toxicity was Grade 0, 1, 2, and 3 in 17, 5, 10, and 5 patients, respectively. Erythema was the most frequent toxicity (36.8%), most commonly affecting the arm (23.5%). Furthermore, all HSRs were classified into: skin, respiratory, digestive, circulatory, and neurological. The completion rate of desensitization was significantly lower in patients with two or more target organs affected (p<0.001). CONCLUSION: The main symptoms of HSRs, the most common sites of HSRs, and the criteria for discontinuing desensitization therapy identified in this study are useful information for the safe implementation of carboplatin desensitization therapy. When you point to this article, it is believed that you are also very interested in this compound(41575-94-4)Name: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) and due to space limitations, I can only present the most important information.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Most of the compounds have physiologically active properties, and their biological properties are often attributed to the heteroatoms contained in their molecules, and most of these heteroatoms also appear in cyclic structures. A Journal, Article, Cancer (Hoboken, NJ, United States) called The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments, Author is Meijer, Annelot J. M.; Li, Kathy H.; Brooks, Beth; Clemens, Eva; Ross, Colin J.; Rassekh, Sharad R.; Hoetink, Alex E.; van Grotel, Martine; van den Heuvel-Eibrink, Marry M.; Carleton, Bruce C., which mentions a compound: 41575-94-4, SMILESS is O=C1C2(CCC2)C(O[Pt]O1)=O.N.N, Molecular C6H12N2O4Pt, Synthetic Route of C6H12N2O4Pt.

Ototoxicity is a common adverse event of cisplatin treatment. The authors investigated the development of cisplatin-induced hearing loss (CIHL) over time in children with cancer by age and examined the influence of other clin. characteristics on the course of CIHL. Data from Canadian patients with childhood cancer were retrospectively reviewed. Hearing loss was graded according to International Society of Pediatric Oncol. criteria. The Kaplan-Meier method was applied to estimate the cumulative incidence of CIHL for the total cohort and according to age. Cox regression models were used to explore the effects of independent variables on CIHL development up to 3 years after the start of therapy. In total, 368 patients with 2052 audiol. assessments were included. Three years after initiating therapy, the cumulative incidence of CIHL was highest in patients aged ≤5 years (75%; 95% confidence interval [CI], 66%-84%), with a rapid increase observed to 27% (95% CI, 21%-35%) at 3 mo and to 61% (95% CI, 53%-69%) at 1 yr, compared with patients aged >5 years (48%; 95% CI, 37%-62%; P < .001). The total cumulative dose of cisplatin at 3 mo (per 100 mg/m2 increase: hazard ratio [HR], 1.20; 95% CI, 1.01-1.41) vincristine (HR, 2.87; 95% CI, 1.89-4.36) and the total duration of concomitantly administered antibiotics (>30 days: HR, 1.85; 95% CI, 1.17-2.95) further influenced CIHL development over time. In young children, the cumulative incidence of CIHL is higher compared with that in older children and develops early during therapy. The course of CIHL is further influenced by the total cumulative dose of cisplatin and other ototoxic (co-)medication. These results highlight the need for audiol. monitoring at each cisplatin cycle.

As far as I know, this compound(41575-94-4)Synthetic Route of C6H12N2O4Pt can be applied in many ways, which is helpful for the development of experiments. Therefore many people are doing relevant researches.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

COA of Formula: C6H12N2O4Pt. Aromatic compounds can be divided into two categories: single heterocycles and fused heterocycles. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about How can the cisplatin analogs with different amine act on DNA during cancer treatment theoretically?. Author is Rahiminezhad, Arezo; Moghadam, Mahboube Eslami; Divsalar, Adeleh; Mesbah, A. Wahid.

Cisplatin is a widely used anti-cancer drug which inhibits the replication and polymerization of DNA mol. while showing some side effects and drug resistance. For this reason, to enhance its therapeutic index, researchers have synthesized several thousand analogs and tested their properties. In this project, several cisplatin analogs were designed to theor. study the biol. activity and lipophilicity effects on amine changes. The amines of the cisplatin mol. were substituted with aliphatic amines in different analogs. Computational methods such as mol. dynamics simulation, mol. docking, and mol. mechanics Poisson-Boltzmann surface area anal. were performed to investigate the binding of six cisplatin derivatives with DNA. The binding affinity and potential interactions of these drugs with double-strand DNA were analyzed. The stability effect of these drugs was investigated via root-mean-square deviation and root-mean-square fluctuation anal., which showed that some analogs can break base-pair interaction at the end of DNA and reduced the stability of DNA. Also, the results revealed that the hydrogen bond is one of the most important factors in the binding of cisplatin′s adduct to DNA. Mol. mechanics Poisson-Boltzmann surface area anal. indicated that electrostatic and van der Waals interactions are the most important deriving forces to the binding of cisplatin′s drug to DNA. Finally, data revealed that cisplatin and the cis-dichloro-dimethylamine-platin tendency for binding to DNA are greater than that of other analogs.

In addition to the literature in the link below, there is a lot of literature about this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))COA of Formula: C6H12N2O4Pt, illustrating the importance and wide applicability of this compound(41575-94-4).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Product Details of 41575-94-4. The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Cervical cancer treatment in Rwanda: Resource-driven adaptations, quality indicators, and patient outcomes.. Author is DeBoer, Rebecca J; Umutoni, Victoria; Bazzett-Matabele, Lisa; Katznelson, Ethan; Nguyen, Cam; Umwizerwa, Aline; Bigirimana, Jean Bosco; Paciorek, Alan; Nsabimana, Nicaise; Ruhangaza, Deogratias; Ntasumbumuyange, Diomede; Shulman, Lawrence N; Triedman, Scott A; Shyirambere, Cyprien.

OBJECTIVE: Most cervical cancer cases and deaths occur in low- and middle-income countries, yet clinical research from these contexts is significantly underrepresented. We aimed to describe the treatment quality, resource-driven adaptations, and outcomes of cervical cancer patients in Rwanda. METHODS: A retrospective cohort study was conducted of all patients with newly diagnosed cervical cancer enrolled between April 2016 and June 2018. Data were abstracted from medical records and analyzed using descriptive statistics, Kaplan Meier methods, and Cox proportional hazards regression. RESULTS: A total of 379 patients were included; median age 54 years, 21% HIV-infected. A majority (55%) had stage III or IV disease. Thirty-four early-stage patients underwent radical hysterectomy. Of 254 patients added to a waiting list for chemoradiation, 114 ultimately received chemoradiation. Of these, 30 (26%) received upfront chemoradiation after median 126 days from diagnosis, and 83 (73%) received carboplatin/paclitaxel while waiting, with a median 56 days from diagnosis to chemotherapy and 207 days to chemoradiation. There was no survival difference between the upfront chemoradiation and prior chemotherapy subgroups. Most chemotherapy recipients (77%) reported improvement in symptoms. Three-year event-free survival was 90% with radical hysterectomy (95% CI 72-97%), 66% with chemoradiation (95% CI 55-75%), and 12% with chemotherapy only (95% CI 6-20%). CONCLUSIONS: Multi-modality treatment of cervical cancer is effective in low resource settings through coordinated care and pragmatic approaches. Our data support a role for temporizing chemotherapy if delays to chemoradiation are anticipated. Sustainable access to gynecologic oncology surgery and expanded access to radiotherapy are urgently needed.

In addition to the literature in the link below, there is a lot of literature about this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))Product Details of 41575-94-4, illustrating the importance and wide applicability of this compound(41575-94-4).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. Author is Quintanilha, Julia C. F.; Wang, Jin; Sibley, Alexander B.; Xu, Wei; Espin-Garcia, Osvaldo; Jiang, Chen; Etheridge, Amy S.; Ratain, Mark J.; Lenz, Heinz-Josef; Bertagnolli, Monica; Kindler, Hedy L.; Dickler, Maura N.; Venook, Alan; Liu, Geoffrey; Owzar, Kouros; Lin, Danyu; Innocenti, Federico.

Meta-anal. of. Germline variants might predict cancer progression. Bevacizumab improves overall survival (OS) in patients with advanced cancers. No biomarkers are available to identify patients that benefit from bevacizumab. A meta-anal. of genome-wide association studies (GWAS) was conducted in 1,520 patients from Phase III trials (CALGB 80303, 40503, 80405 and ICON7), where bevacizumab was randomized to treatment without bevacizumab. We aimed to identify genes and single nucleotide polymorphisms (SNPs) associated with survival independently of bevacizumab treatment or through interaction with bevacizumab. A cause-specific Cox model was used to test the SNP-OS association in both arms combined (prognostic), and the effect of SNPs-bevacizumab interaction on OS (predictive) in each study. The SNP effects across studies were combined using inverse variance. Findings were tested for replication in advanced colorectal and ovarian cancer patients from The Cancer Genome Atlas (TGCA). In the GWAS meta-anal., patients with rs680949 in PRUNE2 experienced shorter OS compared to patients without it (P = 1.02 x 10-7, hazard ratio [HR] = 1.57, 95% confidence interval [CI] 1.33-1.86), as well as in TCGA (P = .0219, HR = 1.58, 95% CI 1.07-2.35). In the GWAS meta-anal., patients with rs16852804 in BARD1 experienced shorter OS compared to patients without it (P = 1.40 x 10-5, HR = 1.51, 95% CI 1.25-1.82) as well as in TCGA (P = 1.39 x 10-4, HR = 3.09, 95% CI 1.73-5.51). Patients with rs3795897 in AGAP1 experienced shorter OS in the bevacizumab arm compared to the nonbevacizumab arm (P = 1.43 x 10-5). The largest GWAS meta-anal. of bevacizumab treated patients identified PRUNE2 and BARD1 (tumor suppressor genes) as prognostic genes of colorectal and ovarian cancer, resp., and AGAP1 as a potentially predictive gene that interacts with bevacizumab with respect to patient survival.

In addition to the literature in the link below, there is a lot of literature about this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), illustrating the importance and wide applicability of this compound(41575-94-4).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)(SMILESS: O=C1C2(CCC2)C(O[Pt]O1)=O.N.N,cas:41575-94-4) is researched.Computed Properties of C22H38NiO4. The article 《Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.》 in relation to this compound, is published in Gynecologic oncology. Let’s take a look at the latest research on this compound (cas:41575-94-4).

INTRODUCTION: Chemotherapy plus radiation (Cis-RT + CP) did not demonstrate superiority in prolonging relapse-free survival compared to chemotherapy alone in patients with stage III or IVA endometrial carcinoma. The impact of treatment on quality of life (QOL), neurotoxicity (NTX) and psychometric properties of the gastrointestinal (GI) symptoms subscale during treatment and up to 1 year are described herein. METHODS: QOL assessments were scheduled at baseline, 6 weeks (post completion of RT (Cis-RT + CP) or prior to cycle 3 (CP)), then 18 weeks (end of treatment) and 70 weeks (1 year after the end of treatment) after starting treatment. QOL instruments included the FACT-En TOI, FACT/GOG-neurotoxicity (Ntx) subscale (short), and the gastrointestinal (GI) symptoms subscale. RESULTS: At the end of treatment, patients receiving Cis-RT + CP reported a statistically significant decreased QOL when compared to CP. The decline in QOL was reflected in physical well-being, functional well-being, and endometrial cancer specific concerns, but the minimally important differences (MID) were not considered clinically meaningful. Patients in both groups reported increased chemotherapy-induced Ntx symptoms with the CP group having worse scores and reaching peak symptoms at the time of chemotherapy completion. Patients on Cis-RT + CP reported statistically significantly worse GI symptoms after radiation therapy compared to patients on CP, this occurred across assessment intervals, though the MID was not meaningful. Psychometric evaluations indicated that the GI symptom scale is reliable, valid, and responsive to change. CONCLUSIONS: PROs indicate that the chemoradiotherapy group experienced worse HRQoL and GI toxicity compared to patients randomized to chemotherapy alone for locally advanced endometrial cancer though based on the MID, these were not clinically meaningful differences. The GI symptom subscale was a reliable and valid scale that has value for future trials. TRIAL REGISTRATION: NCT00942357.

In addition to the literature in the link below, there is a lot of literature about this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), illustrating the importance and wide applicability of this compound(41575-94-4).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

In organic chemistry, atoms other than carbon and hydrogen are generally referred to as heteroatoms. The most common heteroatoms are nitrogen, oxygen and sulfur. Now I present to you an article called Outcomes of prophylactic cranial irradiation in patients with small cell lung cancer in the modern era of baseline magnetic resonance imaging of the brain, published in 2022, which mentions a compound: 41575-94-4, mainly applied to prophylactic cranial irradiation human lung cancer brain magnetic imaging; Small-cell lung cancer; prophylactic cranial irradiation; brain magnetic resonance imaging; brain metastases; limited-stage small-cell lung cancer; extensive-stage small-cell lung cancer, Application In Synthesis of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II).

For decades many patients with small cell lung cancer (SCLC) have been offered prophylactic cranial irradiation (PCI) to prevent brain metastases (BM). However, the role of PCI is debated in the modern era of increased brain magnetic resonance imaging (MRI) availability. BM in SCLC patients may respond to chemotherapy, and if a neg. MRI is used in the decision to use of PCI in the treatment strategy, the timing of brain MRI may be crucial when evaluating the effect of PCI. This retrospective study investigates the impact of PCI outcomes in patients with SCLC staged with brain MRI prior to chemotherapy. This study included 245 patients diagnosed SCLC/mixed NSCLC-SCLC treated between 2012 and 2019. The population was analyzed sep. for limited disease (LS-SCLC) and extensive disease (ES-SCLC). Patients were divided into groups based on baseline brain MRI prior to chemotherapy and PCI. The primary endpoint was time to symptomatic BM. Secondary endpoints were overall survival (OS), and progression-free survival (PFS). In patients with LS-SCLC staged with brain MRI the probability of developing symptomatic BM at one year was 4% vs. 22% (p < 0.05), median OS was 55 vs. 24 mo (p < 0.05), and median PFS was 30 vs. 10 mo (p < 0.05) with and without PCI, resp. No differences in probability of symptomatic BM and survival outcomes were observed in ES-SCLC. In a multivariate regression anal., no variables were statistically significant associated with the risk of developing symptomatic BM in patients with LS-SCLC and ES-SCLC. For patients with ES-SCLC staged with brain MRI, PS (HR = 3.33, CI; 1.41-7.89, p < 0.05) was associated with poor survival. This study found that PCI in LS-SCLC patients staged with brain MRI had lower incidence of symptomatic BM and improved survival outcomes suggesting PCI as standard of care. Similar benefit of PCI in patients with ES-SCLC was not found. There are many compounds similar to this compound(41575-94-4)Application In Synthesis of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). if you want to know more, you can check out my other articles. I hope it will help you，maybe you’ll find some useful information.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Carboplatin-paclitaxel in triple-negative metastatic breast cancer during pregnancy with neoplastic thrombosis.》. Authors are Monari, Francesca; Grandi, Giovanni; Guidotti, Isotta; Torcetta, Francesco; Battista, Rachele; Coluccio, Valeria; Piombino, Claudia; Moscetti, Luca; Neri, Isabella; Toss, Angela.The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).Recommanded Product: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). Through the article, more information about this compound (cas:41575-94-4) is conveyed.

The treatment of breast cancer (BC) diagnosed during pregnancy is a challenging situation for the patient, family and healthcare providers. Here we describe the case of a 35-year-old woman diagnosed with a triple-negative breast cancer relapse during pregnancy. She previously underwent neoadjuvant chemotherapy without any response, subsequent left skin sparing mastectomy plus axillary node dissection and radiation therapy to the chest wall and supraclavicular lymph nodes. Two years later, during her first single pregnancy, the patient presented a subclavian vein thrombosis and a BC relapse to locoregional lymph nodes. At 24 weeks of gestation, a first line treatment with weekly paclitaxel and carboplatin was started. Considering the disease progression after two complete cycles of chemotherapy, the patient had an elective caesarean section at 32+6 weeks. A full-body CT-scan and a PET-scan after the delivery showed a massive neoplastic thrombosis involving the left jugular, brachiocephalic and internal mammary vein, as well the superior vena cava and the right atrium. Few data are available on platinum-based chemotherapy during pregnancy in BC patients. Nevertheless, the choice of therapy was conditioned by the previous absence of response to anthracycline and taxane. In case of BC diagnosis during pregnancy, a multidisciplinary management as in the case described is recommended to increase the chance of survival both for the patients and their babies.

There are many compounds similar to this compound(41575-94-4)Recommanded Product: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). if you want to know more, you can check out my other articles. I hope it will help you，maybe you’ll find some useful information.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Epoxy compounds usually have stronger nucleophilic ability, because the alkyl group on the oxygen atom makes the bond angle smaller, which makes the lone pair of electrons react more dissimilarly with the electron-deficient system. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II).

Few clin. studies have been designed for elderly patients with locally advanced non-small cell lung cancer (NSCLC). We conducted a phase I study to evaluate the tolerability of carboplatin/nab-paclitaxel and concurrent thoracic radiotherapy in elderly patients with locally advanced NSCLC. The eligibility criteria were: unresectable stage III NSCLC, performance status 0 or 1, and age ≥75 years. Eligible patients received 6 wk of weekly carboplatin/nab-paclitaxel and concurrent thoracic radiotherapy with a total dose of 64 Gy in 32 fractions. Carboplatin was fxed to an area under the plasma concentration time curve (AUC) of 2 mg/mL/min, and the recommended dose of nab-paclitaxel was evaluated using a dose-escalation study (30 or 40 mg/m2). Tolerability at the recommended dose was evaluated in an expansion study. Nineteen patients were enrolled at four institutions, all of whom were eligible and assessable. The recommended nab-paclitaxel dose was set at 30 mg/m2 because two patients experienced dose-limiting toxicity at 40 mg/m2. The treatment completion rate of the 17 patients analyzed at the recommended dose was 100% (80% confdence interval (CI), 83.8-100%). The overall response rate was 76.5%, and the median progression free survival was 13.4 mo (95% CI, 4.2-21.4 mo). Common grade 3 and 4 toxicities included leukopenia (23.5%), neutropenia (17.6%), anemia (5.9%), and infection (5.9%). One treatment-related death due to pneumonitis was observed six months after the end of the study. In conclusion, carboplatin/nab-paclitaxel and concurrent thoracic radiotherapy show good tolerability and exhibit promising efcacy in elderly patients with locally advanced NSCLC.

There are many compounds similar to this compound(41575-94-4)Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). if you want to know more, you can check out my other articles. I hope it will help you，maybe you’ll find some useful information.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics